MTI-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells

被引:53
作者
Sodek, K. L.
Ringuette, M. J.
Brown, T. J.
机构
[1] Samuel Lunenfeld Res Inst, Dept Obstet & Gynecol, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON M5S 3G5, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
MTI-MMP; ovarian cancer; invasion; motility; collagen I; E-cadherin;
D O I
10.1038/sj.bjc.6603863
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Membrane- type 1 matrix metalloproteinase ( MTI- MMP), a transmembrane metalloprotease that plays an important role in the invasion of many solid tumour types, promotes pericellular matrix degradation and may also stimulate tumour cell motility. As both these processes are key contributors to intraperitoneal ovarian tumour metastasis, we examined six ovarian cancer cell lines to determine whether MTI is a critical mediator of invasive behaviour for this tumour type. Our results indicated that only those cell lines that expressed MTI were capable of penetrating a type I collagen barrier, with the capacity for both matrix degradation and invasion reflecting endogenous MTIexpression level. Ectopic MTI expression endowed an invasive phenotype upon cell lines lacking MTI that were previously non- invasive, indicating the crucial role of this protease. Conversely, invasion was abolished by tissue inhibitor of metalloproteinase- 2 ( TIMP- 2), a potent inhibitor of MTI, yet was minimally affected when other ( secreted) MMPs were inhibited using TIMP-I and the gelatinase inhibitor SB- 3CT. Whereas collagen I degradation was strikingly accelerated by ectopic MTI expression, cell motility remained unchanged. We conclude that MTI is necessary for collagen I invasion by ovarian cancer cells, and that its requisite activity is the promotion of matrix degradation, with no impact on cell motility.
引用
收藏
页码:358 / 367
页数:10
相关论文
共 69 条
[1]   Membrane type 1-matrix metalloproteinase expression is regulated by E-cadherin through the suppression of mitogen-activated protein kinase cascade [J].
Ara, T ;
Deyama, Y ;
Yoshimura, Y ;
Higashino, F ;
Shindoh, M ;
Matsumoto, A ;
Fukuda, H .
CANCER LETTERS, 2000, 157 (02) :115-121
[2]   Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: Defining the stages of invadopodia formation and function [J].
Artym, VV ;
Zhang, Y ;
Seillier-Moiseiwitsch, FO ;
Yamada, KM ;
Mueller, SC .
CANCER RESEARCH, 2006, 66 (06) :3034-3043
[3]   Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches [J].
Auersperg, N ;
Ota, T ;
Mitchell, GWE .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2002, 12 (06) :691-703
[4]  
Aznavoorian S, 2001, CANCER RES, V61, P6264
[5]   Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers [J].
Burleson, KM ;
Hansen, LK ;
Skubitz, APN .
CLINICAL & EXPERIMENTAL METASTASIS, 2004, 21 (08) :685-697
[6]   Membrane type I-matrix metalloproteinase promotes human prostate cancer invasion and metastasis [J].
Cao, J ;
Chiarelli, C ;
Kozarekar, P ;
Adler, HL .
THROMBOSIS AND HAEMOSTASIS, 2005, 93 (04) :770-778
[7]   Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration [J].
Cao, J ;
Kozarekar, P ;
Pavlaki, M ;
Chiarelli, C ;
Bahou, WF ;
Zucker, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (14) :14129-14139
[8]   Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization [J].
Chen, WT ;
Wang, JY .
INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 :361-371
[9]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
[10]   The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma [J].
Davidson, B ;
Goldberg, I ;
Gotlieb, WH ;
Kopolovic, J ;
Ben-Baruch, G ;
Nesland, JM ;
Reich, R .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2002, 187 (1-2) :39-45